Skip to main content
. 2022 Dec 22;9:1071732. doi: 10.3389/fmed.2022.1071732

FIGURE 3.

FIGURE 3

Graphical representation of (A) the number of patients reaching the different time-points during follow-up while on canakinumab treatment; (B) the frequency of complete response, partial response, and poor response in the whole group of patients enrolled at the different tume-points.